1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 106. Skrepnek G H, Armstrong E P, Malone D C, Abarca J, Murphy J E, Grizzle A J, Rehfeld R A, Woosley R L. Workload and availability of technology in metropolitan community pharmacies. Journal of the American Pharmacists Association : JAPhA. 2006; 46 : 154-60
107. Skrepnek G H, Abarca J, Malone D C, Armstrong E P, Shirazi F M, Woosley R L. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. The Annals of pharmacotherapy. 2005; 39 : 1785-91
108. Skrepnek G H. Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert review of pharmacoeconomics & outcomes research. 2005; 5 : 603-23
109. Skrepnek G H. Regression methods in the empiric analysis of health care data. Journal of managed care pharmacy : JMCP. 2005; 11 : 240-51
110. Skrepnek G H, Ballard E E. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005; 25 : 325-34
Grants
- 1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.
2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.
3. HIV Adherence Services. Start Date: 2022. End Date: 2023.
4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.
5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.
Awards and Honors
no results
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.